Product Details
Alternative Name: | IL-1F2, Interleukin-1β |
|
Source: | Produced in E. coli. Human IL-1β (interleukin-1β) (aa 117-270) is fused to a linker peptide (10 aa) and an N-terminal FLAG®-tag. |
|
UniProt ID: | P01584 |
|
Concentration: | 0.1mg/ml after reconstitution. |
|
Formulation: | Lyophilized. Contains PBS. |
|
Purity: | ≥90% (SDS-PAGE) |
|
Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Associates of CAPE COD Inc.). |
|
Specificity: | Binds to human IL-1R (interleukin-1 receptor). |
|
Reconstitution: | Reconstitute with 100µl sterile water. |
|
Shipping: | Blue Ice |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
|
Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
|
Technical Info/Product Notes: | Historical data has shown that IL-1β activates the NF-κB pathway.
FLAG is a registered trademark of Sigma-Aldrich Co. |
|
Regulatory Status: | RUO - Research Use Only |
|
Figure: IL-1b activity was assessed by its ability to induce the activation of the NF-kB pathway. IkBa degradation was detected by Western blotting.
Method: Hela cells were grown to confluence in 6 well plates. IL-1b was diluted at the indicated concentrations in 500µl DMEM/Nut.Mix.F-12 10% fetal calf serum and added to the wells after being washed once with the same media. Cells were collected after 30 min and lysed. 100µg of cellular extract were separated on a SDS-PAGE and transferred on a nitrocellulose membrane. IkBa degradation was detected with a rabbit polyclonal antibody to IkBa and a goat anti-rabbit HRP-conjugated secondary antibody. Degradation of IkBa was detected at 10pg/µl IL-1b, under these conditions.
Please mouse over
Product Literature References
CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation: T. Elmetwali, et al.; Sci. Rep.
10, 342 (2020),
Abstract;
Full Text
Regulator of G protein signaling 4 is a novel target of GATA-6 transcription factor: Y. Zhang, et al.; Biochem. Biophys. Res. Commun.
483, 923 (2017),
Abstract;
Insulin-secreting beta-cell dysfunction induced by human lipoproteins: M.E. Roehrich, et al.; J. Biol. Chem.
278, 18368 (2003),
Abstract;
Full Text
General Literature References
Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?: J.M. Dayer; J. Rheumatol. Suppl.
65, 10 (2002),
Abstract;
The in vivo effects of interleukin 1. I. Bone marrow cells are induced to cycle after administration of interleukin 1: R. Neta, et al.; J. Immunol.
139, 1861 (1987),
Abstract;
Human interleukin 1: I. Gery & J.A. Schmidt; Meth. Enzymol.
116, 456 (1985),
Abstract;
Interleukin 1: an immunological perspective: S.K. Durum, et al.; Annu. Rev. Immunol.
3, 263 (1985),
Abstract;